Pancreatic Cancer Research

ResearcherHenry Ford Health + Michigan State University Health SciencesActive in the last 2 years

Howard C. Crawford

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9360-3019; OpenAlex author ID A5054373028; NIH RePORTER profile ID 1938448. Sources: OpenAlex.

Their work

Papers
48 (first author 4, last author 6)
Trials
0
Grants
7
Labs led
5
Collaborators
208
Papers, trials and grants by year

2012: 1 paper · 2013: 1 grant · 2014: 1 paper · 2015: 2 papers, 1 grant · 2016: 3 papers, 1 grant · 2017: 1 paper · 2018: 1 paper · 2019: 4 papers · 2020: 7 papers · 2021: 8 papers, 1 grant · 2022: 7 papers · 2023: 4 papers · 2024: 2 papers, 1 grant · 2025: 4 papers · 2026: 3 papers, 2 grants

Papers 48

  1. Spatial Transcriptomics on a Diverse Pancreatic Cancer Cohort Reveals Race-Related Differences in Tumor Subtypes and Immune Microenvironments. Co-author DOI 10.1158/0008-5472.can-25-2748↗
  2. Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer. Co-author DOI 10.1186/s12943-025-02340-8↗
  3. HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α Co-author DOI 10.64898/2026.10.02.754697↗
  4. Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer. Last author DOI 10.1016/j.devcel.2024.12.003↗
  5. Primary and metastatic cellular landscapes in human pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113012↗
  6. Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells. Co-author DOI 10.1158/1078-0432.ccr-24-2183↗
  7. HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-2200↗
  8. Corrigendum to "scRNA-Seq and imaging mass cytometry analyses unveil iNKT cells-mediated anti-tumor immunity in pancreatic cancer liver metastasis" [Cancer Let… Co-author DOI 10.1016/j.canlet.2024.217071↗
  9. Rethinking the Roles of Cancer-Associated Fibroblasts in Pancreatic Cancer. First author DOI 10.1016/j.jcmgh.2024.01.022↗
  10. KMT2D links TGF-β signaling to noncanonical activin pathway and regulates pancreatic cancer cell plasticity. Co-author DOI 10.1002/ijc.34528↗
  11. scRNA-Seq and imaging mass cytometry analyses unveil iNKT cells-mediated anti-tumor immunity in pancreatic cancer liver metastasis. Co-author DOI 10.1016/j.canlet.2023.216149↗
  12. A Bitter Taste Receptor as a Novel Molecular Target on Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ph16030389↗
  13. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Co-author DOI 10.7554/elife.80721↗
  14. KDM6A Regulates Cell Plasticity and Pancreatic Cancer Progression by Noncanonical Activin Pathway. Co-author DOI 10.1016/j.jcmgh.2021.09.014↗
  15. Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer. Co-author DOI 10.1038/s41389-022-00434-2↗
  16. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Co-author DOI 10.1038/s41467-021-27088-9↗
  17. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s43018-022-00463-1↗
  18. KDM6A Loss Recruits Tumor-Associated Neutrophils and Promotes Neutrophil Extracellular Trap Formation in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0968↗
  19. Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. Co-author DOI 10.1371/journal.pgen.1010315↗
  20. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Co-author DOI 10.7554/elife.73245↗
  21. Disease-induced immunomodulation at biomaterial scaffolds detects early pancreatic cancer in a spontaneous model. Co-author DOI 10.1016/j.biomaterials.2020.120632↗
  22. The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice. Last author DOI 10.1016/j.jcmgh.2020.08.011↗
  23. Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer. Last author DOI 10.1016/j.jcmgh.2021.07.006↗
  24. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Co-author DOI 10.1038/s41467-021-24859-2↗
  25. ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer. Co-author DOI 10.1101/gad.344184.120↗
  26. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1. Last author DOI 10.1158/0008-5472.can-20-3929↗
  27. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  28. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. Co-author DOI 10.26508/lsa.202000935↗
  29. Discoidin Domain Receptor 1 (DDR1) Is Necessary for Tissue Homeostasis in Pancreatic Injury and Pathogenesis of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.ajpath.2020.03.020↗
  30. Differential Contribution of Pancreatic Fibroblast Subsets to the Pancreatic Cancer Stroma. Co-author DOI 10.1016/j.jcmgh.2020.05.004↗
  31. An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development. Co-author DOI 10.1038/s41467-020-16309-2↗
  32. Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition. Co-author DOI 10.1038/s41598-020-67814-9↗
  33. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. Co-author DOI 10.1038/s43018-020-00121-4↗
  34. Carcinogenesis of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1053/j.gastro.2020.02.059↗
  35. Early detection and imaging strategies to reveal and target developing pancreatic cancer Co-author DOI 10.1080/14737140.2020.1720654↗
  36. Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. Co-author DOI 10.1016/j.celrep.2019.09.056↗
  37. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2019.02.001↗
  38. Putting the Cell of Origin for Pancreatic Cancer Into its Proper Context. Co-author DOI 10.1016/j.jcmgh.2019.08.001↗
  39. Epithelial-Stromal Interactions in Pancreatic Cancer. First author DOI 10.1146/annurev-physiol-020518-114515↗
  40. HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. Co-author DOI 10.7554/elife.33947↗
  41. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Co-author DOI 10.1038/s41467-017-01967-6↗
  42. NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2016.06.056↗
  43. Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer. Co-author DOI 10.1073/pnas.1512603113↗
  44. PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. Last author DOI 10.1101/gad.291021.116↗
  45. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Co-author DOI 10.1038/nm.3973↗
  46. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. Co-author DOI 10.15252/embj.201489574↗
  47. Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-13-0557-t↗
  48. KRAS above and beyond - EGFR in pancreatic cancer First author DOI 10.18632/oncotarget.750↗

Grants 7

  1. Collagen Signaling in Pancreatic Cancer R01CA281198↗
  2. Fibroblast orchestration of the immune response in pancreatic cancer U01CA274154↗
  3. Metaplastic Tuft Cells in Pancreatic Cancer R01CA247516↗
  4. Interrupting Cellular Crosstalk in the Immunosuppressive Microenvironment of Pancreas Cancer U01CA224145↗
  5. Discoidin Domain Receptors: Novel Players in Pancreatitis and Pancreatic Preneoplasia R21CA191347↗
  6. ADAM17 in pancreatic cancer and pancreatitis R01CA159222↗
  7. Phosphatidylinositol 3-kinase and prevention of pancreatic cancer R01CA136754↗

Closest collaborators

The 25 strongest of 208 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Pasca di Magliano · 23 shared papers, 2 shared grants, 2019–2026 · strength 4.31
  2. Nina G. Steele · 15 shared papers, 2020–2026 · strength 2.11
  3. Costas Andreas Lyssiotis · 10 shared papers, 1 shared grant, 2019–2026 · strength 1.82
  4. Timothy L. Frankel · 5 shared papers, 1 shared grant, 2019–2026 · strength 1.37
  5. Rafael A. Fridman · 1 shared paper, 2 shared grants, 2016–2026 · strength 1.36
  6. Ian M. Loveless · 7 shared papers, 2023–2026 · strength 1.33
  7. Samantha B. Kemp · 10 shared papers, 2019–2025 · strength 1.23
  8. Yaqing Zhang · 10 shared papers, 2019–2023 · strength 1.11
  9. Jean-Philippe Francois Marie Coppe · 1 shared grant, 2026 · strength 1.00
  10. Daniel James Salas-Escabillas · 6 shared papers, 2021–2026 · strength 0.97
  11. Debora Barbosa Vendramini Costa · 4 shared papers, 2024–2026 · strength 0.96
  12. Ralph A. Francescone III · 4 shared papers, 2024–2026 · strength 0.96
  13. Eileen S. Carpenter · 8 shared papers, 2020–2025 · strength 0.92
  14. Filip Bednar · 8 shared papers, 2020–2025 · strength 0.92
  15. Katelyn L. Donahue · 6 shared papers, 2020–2025 · strength 0.75
  16. Zeribe C. Nwosu · 7 shared papers, 2021–2023 · strength 0.74
  17. Jiaqi Shi · 6 shared papers, 2018–2025 · strength 0.73
  18. Christopher J. Halbrook · 7 shared papers, 2016–2023 · strength 0.63
  19. Megan T. Hoffman · 6 shared papers, 2016–2025 · strength 0.61
  20. Benjamin Allen · 5 shared papers, 2020–2025 · strength 0.57
  21. Bin Chen · 3 shared papers, 2023–2026 · strength 0.56
  22. Mats E. Ljungman · 5 shared papers, 2016–2023 · strength 0.52
  23. Peter Störz · 2 shared papers, 2020 · strength 0.43
  24. Ling Huang · 3 shared papers, 2015–2026 · strength 0.42
  25. Naomi Yamamoto · 2 shared papers, 2025–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.